Abstract
There is increasing evidence linking the incidence of certain cancers to low serum Vitamin D levels. The active metabolite of Vitamin D, calcitriol (1, 25-Dihydroxyvitamin D3, 1,25(OH)2D3) apart from a crucial role in maintaining mineral homeostasis and skeletal functions, has antiproliferative, apoptosis and differentiation inducing as well as immunomodulatory effects in cancer. In studying the role of 1,25(OH)2D3 in cancer, it is imperative to examine the potential pathways that control local tissue levels of 1,25(OH)2D3. The enzyme CYP24A1 or 24-hydroxylase converts 1,25(OH)2D3 to inactive calcitroic acid. Extra-renal production of this enzyme is observed and has been increasingly recognized as present in cancer cells. This enzyme is rate limiting for the amount of local 1,25(OH)2D3 in cancer tissues and elevated expression is associated with an adverse prognosis. The gene that encodes CYP24A1 has been reported as an oncogene and may contribute to tumor aggressiveness by abrogating local anti-cancer effects of 1,25(OH)2D3. It is imperative to study the regulation of CYP24A1 in cancer and especially the local metabolism of 1,25(OH)2D3 in cancer cells. CYP24A1 may be a predictive marker of 1,25(OH)2D3 efficacy in patients with cancer as an adjunctive therapy. The following review summarizes the available literature on CYP24A1 as it relates to 1,25(OH)2D3 in cancer and outlines potential ways to inhibit CYP24A1 in an effort to improve the efficacy of exogenous 1,25(OH)2D3.
Anti-Cancer Agents in Medicinal Chemistry
Title: The Vitamin D/CYP24A1 Story in Cancer
Volume: 10 Issue: 3
Author(s): Amanda N. King, David G. Beer, Paul J. Christensen, Robert U. Simpson and Nithya Ramnath
Affiliation:
Keywords: Vitamin D, cancer, CYP24A1, prognosis
Abstract: There is increasing evidence linking the incidence of certain cancers to low serum Vitamin D levels. The active metabolite of Vitamin D, calcitriol (1, 25-Dihydroxyvitamin D3, 1,25(OH)2D3) apart from a crucial role in maintaining mineral homeostasis and skeletal functions, has antiproliferative, apoptosis and differentiation inducing as well as immunomodulatory effects in cancer. In studying the role of 1,25(OH)2D3 in cancer, it is imperative to examine the potential pathways that control local tissue levels of 1,25(OH)2D3. The enzyme CYP24A1 or 24-hydroxylase converts 1,25(OH)2D3 to inactive calcitroic acid. Extra-renal production of this enzyme is observed and has been increasingly recognized as present in cancer cells. This enzyme is rate limiting for the amount of local 1,25(OH)2D3 in cancer tissues and elevated expression is associated with an adverse prognosis. The gene that encodes CYP24A1 has been reported as an oncogene and may contribute to tumor aggressiveness by abrogating local anti-cancer effects of 1,25(OH)2D3. It is imperative to study the regulation of CYP24A1 in cancer and especially the local metabolism of 1,25(OH)2D3 in cancer cells. CYP24A1 may be a predictive marker of 1,25(OH)2D3 efficacy in patients with cancer as an adjunctive therapy. The following review summarizes the available literature on CYP24A1 as it relates to 1,25(OH)2D3 in cancer and outlines potential ways to inhibit CYP24A1 in an effort to improve the efficacy of exogenous 1,25(OH)2D3.
Export Options
About this article
Cite this article as:
N. King Amanda, G. Beer David, J. Christensen Paul, U. Simpson Robert and Ramnath Nithya, The Vitamin D/CYP24A1 Story in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (3) . https://dx.doi.org/10.2174/1871520611009030213
DOI https://dx.doi.org/10.2174/1871520611009030213 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti- Inflammatory Role for the Cannabinoids
Current Clinical Pharmacology Proteomics Studies in Oncology Towards Personalized Medicine in Public Health: Opportunities and Challenges for OMICS Research in Iran
Current Pharmacogenomics and Personalized Medicine The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting
Current Molecular Medicine Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications
Current Nutrition & Food Science Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Radiolabeled Glucose Derivatives for Tumor Imaging Using SPECT and PET
Current Medicinal Chemistry Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Celecoxib A Selective COX-2 Inhibitor Mitigates Fibrosis but not Pneumonitis Following Lung Irradiation: A Histopathological Study
Current Drug Therapy Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Clonetics
Current Drug Metabolism The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation Tumour Reactions to Hypoxia
Current Molecular Medicine Status of Anti-Lung Cancer Drug Patents Applications in China from 2003 to 2012
Recent Patents on Anti-Cancer Drug Discovery Editorial A New Year of Excellence
Current Molecular Medicine Bothrops pauloensis Snake Venom Toxins: The Search for New Therapeutic Models
Current Topics in Medicinal Chemistry Lycorine and its Derivatives for Anticancer Drug Design
Mini-Reviews in Medicinal Chemistry